Impaired Vascular Mechano-transduction in a Transgenic Mouse Model of CADASIL Arteriopathy

Caroline Dubroca, MSc; Pierre Lacombe, PhD; Valérie Domenga; Jacqueline Maciazeck; Bernard Levy, MD, PhD; Elisabeth Tournier-Lasserve, MD; Anne Joutel, MD, PhD; Daniel Henrion, PharmD, PhD

Background and Purpose — CADASIL is an inherited small-vessel disease responsible for lacunar strokes and cognitive impairment. The disease is caused by highly stereotyped mutations in Notch3, the expression of which is highly restricted to vascular smooth muscle cells (VSMCs). The underlying vasculopathy is characterized by degeneration of VSMCs and the accumulation of granular osmiophilic material (GOM) and Notch3 protein within the cell surface of these cells. In this study, we assessed early functional changes related to the expression of mutant Notch3 in resistance arteries.

Methods — Vasomotor function was examined in vitro in arteries from transgenic mice that express a mutant Notch3 in VSMC. Tail artery segments from transgenic and normal wild-type male mice were mounted on small-vessel arteriographs, and reactivity to mechanical (flow and pressure) forces and pharmacological stimuli were determined. Mice were studied at 10 to 11 months of age when VSMC degeneration, GOM deposits, and Notch3 accumulation were not yet present.

Results — Passive arterial diameter, contraction to phenylephrine, and endothelium-dependent relaxation to acetylcholine were unaffected in transgenic mice. By contrast, flow-induced dilation was significantly decreased and pressure-induced myogenic tone significantly increased in arteries from transgenic mice compared with wild-type mice.

Conclusions — This is the first study to our knowledge providing evidence that mutant Notch3 impairs selectively the response of resistance arteries to flow and pressure. The data suggest an early role of vascular dysfunction in the pathogenic process of the disease. (Stroke. 2005;36:113-117.)

Key Words: CADASIL ■ cognitive disorders ■ lacunar infarction ■ mice, transgenic

CADASIL (cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is an inherited small-vessel disease characterized by recurrent ischemic strokes, cognitive impairment, and premature death.1-3 On neuropathological examination, brains show a diffuse myelin loss and multiple small deep infarcts located within the white matter and basal ganglia. These changes are caused by a distinctive arteriopathy characterized by a progressive degeneration of vascular smooth muscle cells (VSMCs) and the accumulation of granular osmiophilic material (GOM) within the basement membrane of these cells. Arterial changes are systemic, although symptoms are restricted to the central nervous system.4,5

CADASIL is caused by highly stereotyped mutations in the Notch3 receptor, which lead to an odd number of cysteine residues within an epidermal growth factor repeat of the extracellular domain.6-9 Recent works demonstrated that VSMC are the primary targets of the pathogenic process. In human adults, expression of Notch3 is highly restricted to VSMC. In CADASIL, there is an abnormal accumulation of Notch3 at the plasma membrane of VSMC because of an impaired clearance of the receptor.10 Consistent with these data, arterial lesions similar to that seen in CADASIL patients develop in transgenic mice that express a mutant Notch3 in VSMCs.11

Functional consequences of vessel changes in the CADASIL pathogenesis process remain to be elucidated. In CADASIL patients, 2 types of lesions affecting resistance arteries have been described that might affect hemodynamic. First, narrowing of the arterial lumen may reduce the baseline blood flow. Second, degeneration of VSMC may impair the vasomotor function. Analysis of transgenic mice that express a mutant Notch3 revealed a third type of lesions that precede VSMC degeneration, GOM deposits, and Notch3 accumulation. These changes are characterized by the disruption of anchorage and adhesion of VSMCs to neighboring cells, as well as cytoskeleton abnormalities of VSMCs.11 Flow (shear stress) is the main mechanical stimulus activating vascular endothelial cells, whereas pressure is the main mechanical stimulus responsible for a sustained vasoconstrictor (myogenic) tone in resistance arteries.12,13 We and others have previously shown that vascular mechanotransduction to shear stress and tensile stress relies on the integrity of cytoskeletal proteins and intercellular communications.12-17 On the basis of the aforementioned observations, we hypothesized...
that these early vascular changes may impair vasomotor function. In the present work, we assessed the vascular reactivity in response to vasoactive agents and mechanical forces in isolated arteries from transgenic mice expressing the Arg90Cys mutant Notch3 protein and wild-type littermate mice. We studied mice at 10 months of age when VSMC cytoskeleton and adhesion defects were present but GOM deposits, Notch3 accumulation, and VSMC degeneration were absent. We focused on the tail caudal arteries because alterations have been especially well-characterized in these vessels.11

Materials and Methods

Animals

The transgenic mouse model of CADASIL arteriopathy used in this study has been described previously.11 In brief, transgenic mice express a mutant human Notch3, carrying the arginine-to cysteine missense mutation at amino acid position 90 in the epidermal growth factor repeat number 2, with the expression driven by the Sm22α promoter. Two independent transgenic founder lines (TgMa and TgVe), established on a C57BL/6 background, that express a low level of mutant Notch3 (<50% of murine Notch3) in the tail arteries have been established, with TgVe expressing a higher level than TgMa. Male transgenic mice heterozygous for the transgene (n = 15, TgMa; n = 15, TgVe) and their wild-type littermates (n = 17) were used. All mice were studied at 10 to 11 months when VSMC degeneration, GOM deposits, and Notch3 accumulation were not yet detected.

The procedure followed in the care and euthanasia of the study animals was in accordance with the European Community Standards on the Care and Use of Laboratory Animals (Ministère de l’Agriculture et Préfecture de Paris, authorizations 00577 and 75-071).

Determination of Blood Pressure

Blood pressure was measured by direct intra-arterial recording. Tygon catheter was inserted into the femoral artery on anesthetized mice with inhaled halothane (1.5%) in O2/N2 mixture. Skin incision was sutured, covered with 2% lidocaine gel, and protected by cotton. Mice were allowed to recover from anesthesia and held under minimal restraint. Rectal temperature was maintained at 37°C to 37.7°C. Recordings of blood pressure were displayed on a chart recorder (RS 3400; Gould). Statistical Analysis

Body weight was not affected by the expression of the mutant protein (41±2 versus 39±2 grams, transgenic mice [line TgMa or TgVe] versus wild-type littermate, n = 8 to 12 per group). Mean arterial blood pressure, measured in femoral artery, was not significantly different between transgenic and wild-type mice (108.3±4.9, n = 6 in TgMa mice; 105.6±2.8, n = 5 in TgVe mice; and 111.6±2.7, n = 5 in wild-type mice).

Pressure-Induced Arterial Tone

In isolated tail caudal arteries, stepwise increases in intraluminal pressure from 0 to 50 mm Hg induced an increase in artery diameter, whereas further step increases in pressure induced no more increase or a decrease in diameter reflecting the development of myogenic tone. The difference between passive diameter and the diameter measured under active tone or “active diameter” at the end of each experiment, arterial segments were superfused with a Ca2+-free physiological salt solution containing ethylenbis-(oxethylentriamino) tetra-acetic acid (EGTA; 2 mM/L) and sodium nitroprusside (10 μmol/L), and pressure steps were repeated to determine the passive diameter of the arteries.14

Results are given in micrometers for artery diameters. Myogenic tone was expressed as active tone (passive diameter–active diameter, in μm) or as the percentage of passive diameter (measured diameter/passive diameter×100). Flow-induced relaxation was expressed as increase in diameter (μm) as a function of shear stress caused by flow in each vessel. Shear stress was calculated for each individual segment of artery as previously described13–15 (τ = 4 η · Q/π · r², where η is viscosity (poise · second · cm⁻²), Q is flow (mL/second), and r is radius (cm)).

In a separate series of arterial segments, we examined dose-dependent contraction of tail arterial segments in response to phenylephrine (10 mM/L to 1 mM/L) and relaxation in response to acetylcholine (10 mM/L to 100 μmol/L) after precontraction with phenylephrine (50% of the maximal contraction) as previously described.15 Contraction in response to phenylephrine was expressed as change in diameter (μm) caused by phenylephrine. Relaxation in response to acetylcholine was expressed as the percentage of dilation of the active tone (preconstriction).15,16

Drugs

HEPES, EGTA, phenylephrine, and acetylcholine were purchased from Sigma. Other reagents were purchased from Prolabo. Drugs were dissolved and diluted in physiological salt solution (HEPES buffer). Concentrations are expressed as final concentration of each drug in the organ bath.
and sodium nitroprusside (10 μmol/L). Under these conditions, arteries responded by a progressive increase in diameter. Internal diameter ranged from 289.6 ± 16.4 μm (pressure, 25 mm Hg) to 346.3 ± 20.1 μm (pressure, 150 mm Hg) in control mice. Passive arterial diameter curves were unaffected in transgenic mice as compared with their wild-type littermates (Figure 1C).

**Flow-Induced Responses**

In arteries submitted to a pressure of 75 mm Hg, increasing flow by step induced a progressive arterial dilation. Arterial dilations were quantified as increases in diameter. Flow (shear stress)-induced dilation was significantly reduced in caudal arteries from transgenic mice as compared with arteries from wild-type mice (Figure 2A).

From the flow and diameter data obtained, wall shear stress was calculated and plotted against the changes in arterial diameter. Figure 2B shows that a given step increase in wall shear stress elicits a significantly attenuated increase in diameter of caudal arteries of transgenic mice compared with those of wild-type mice.

**Responses to Vasoactive Agents**

We examined contraction of tail caudal arteries from transgenic and wild-type mice in response to phenylephrine. All arteries contracted in a dose-dependent manner in response to phenylephrine. Vasoconstriction in response to phenylephrine was similar in transgenic and wild-type mice (Figure 3A).
To study vasorelaxation, precontraction was matched in arteries from transgenic and wild-type mice. Acetylcholine induces an endothelium-dependent relaxation. Tail caudal arteries relaxed in a dose-dependent fashion in response to acetylcholine. Responses to acetylcholine were not impaired in transgenic mice as compared with their wild-type littermates (Figure 3B).

**Discussion**

In this study, we showed that transgenic mice expressing a CADASIL mutant Notch3 in VSMCs exhibited a significant increase in pressure-induced contraction and a significant decrease in flow-induced dilation in isolated caudal arteries. Vascular dysfunction was detected in 10-month-old transgenic mice, when mutant arteries exhibit disruption of adhesion of VSMCs to neighboring endothelial cells and VSMCs, as well as cytoskeleton abnormalities of VSMCs characterized by an increased number of dense plaques and dense bands. In contrast, phenylephrine-induced contraction and acetylcholine-induced dilation were unaffected in these transgenic mice, indicating that the defective transduction of mechanical forces did not arise from a global dysfunction of VSMC. Together, the data indicate that transgenic mice exhibit a specific defect in the transduction of shear and tensile stress into dilation and constriction respectively. Impaired mechanotransduction with preserved agonist or receptor-induced tone has been previously reported in mice lacking vimentin or dystrophin. Thus, our findings further support the notion that mechanical forces (flow, pressure) and chemical stimuli act, at least in great part, through different pathways.

The specific molecular basis for the mechanotransduction defect in Notch3 mutant arteries remains to be elucidated. Both myogenic tone and flow-mediated dilation depend on cytoskeleton integrity and cell-to-cell force transmission through the cytoskeleton, integrins, and the extracellular matrix. Previous works showed that pressure-induced arterial tone involved an initial calcium entry into VSMCs, subsequent activation of signaling pathways (PKC, PLC, Rho-A, . . .) that sensitized the contractile apparatus to calcium, and further resulted in the stimulation of actin polymerization in VSMCs. Increased myogenic tone likely arises from a direct deleterious effect of mutant Notch3, expression of which was specifically targeted in VSMCs. Ultrastructural analyses are consistent with an increased actin polymerization in SMCs of mutant arteries. In contrast, impaired flow-induced dilation, which primarily involves endothelial cells, likely results from an indirect effect of mutant Notch3. Ultrastructural changes of endothelial cells have been detected in mutant arteries. Additionally, one might speculate that defective myoendothelial communications or even a chronic change in smooth muscle tone could account for this specific endothelial cell dysfunction. Additional studies are required to address this issue.

Previous studies reported in CADASIL patients an impaired cerebral vasoreactivity, as determined by attenuated vasodilation to inhaled carbon dioxide or acetazolamide, and abnormal vasoconstrictor reactivity in isolated small gluteal arteries. Of note, all 3 studies included essentially symptomatic patients with a mean age older than 45 years, an age when the pathological hallmarks of the CADASIL arteriopathy, including GOM deposits, Notch3 accumulation, and VSMC degeneration, are already apparent. Thus, these human studies have been difficult to interpret because it was unclear whether impaired vasoreactivity had a primary responsibility in the pathogenic process and whether it arose from vascular cells dysfunction or degeneration. In the present study, we demonstrate that vascular mechanotransduction is impaired very early, before the appearance of the pathological hallmarks of CADASIL. Thus, our findings suggest an early role of vascular dysfunction in the pathogenic process of the disease.
Reduced cerebral blood flow has been demonstrated in CADASIL patients using positron emission tomography, MRI bolus tracking, or phase contrast. Pressure and flow are 2 mechanical stimuli that determine the basal vascular tone in resistance arteries and allow for a rapid adaptation to changes in blood flow and pressure. Attenuation in flow-induced dilation might lead to a lesser adaptation to increases in blood flow in organs when a metabolic need requires a higher blood supply. Similarly, increased myogenic tone might lead to a lesser adaptation to decreases in blood pressure. Because there is no organ in the body as dependent as the brain on a continuous supply of blood and pressure, is early and selectively impaired in arteries with small stress might reduce cerebral blood flow sufficiently to cause ischemic cell injury.

In conclusion, the present study provides the first evidence to our knowledge that vascular reactivity to the mechanical factors, flow and pressure, is early and selectively impaired in arteries expressing a CADASIL mutant Notch3. Treatments that improve vascular mechanotransduction could be beneficial in Notch3 mutation carriers at risk for the CADASIL disease.

Acknowledgments
This work was supported by funds from CADASIL foundation of America, grants from Fondation pour la Recherche sur le Cerveau and GIS Maladies Rares to A.J., and by funds from Fondation pour la Recherche Médicale to D.H.C.D. is a recipient of a Grant from Fondation pour la Recherche Médicale.

References
Impaired Vascular Mechanotransduction in a Transgenic Mouse Model of CADASIL Arteriopathy
Caroline Dubroca, Pierre Lacombe, Valérie Domenga, Jacqueline Maciazek, Bernard Levy, Elisabeth Tournier-Lasserve, Anne Joutel and Daniel Henrion

Stroke. 2005;36:113-117; originally published online November 29, 2004;
doi: 10.1161/01.STR.0000149949.92854.45
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/36/1/113

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/